Five postpartum mothers died after C‑section surgeries at two government hospitals in Kota, Rajasthan, after receiving counterfeit oxytocin injections. Laboratory tests confirmed the vials contained only water, leaving the women vulnerable to severe postpartum hemorrhage. The incident underscores India's persistent drug‑quality crisis and the urgent need for stricter oversight.
Key Takeaways
- Five mothers died in Kota hospitals after receiving counterfeit oxytocin injections.
- Lab analysis showed the vials contained only water, no active ingredient.
- Regulators revoked pharma licences and called for a three‑tier drug testing framework.
In May 2026, two government hospitals in Kota, Rajasthan reported the deaths of five women who had undergone Caesarean sections. Subsequent laboratory investigations revealed that the oxytocin vials administered to these patients belonged to a specific batch that was essentially filled with water, lacking any pharmacologically active compound. Without the uterotonic effect of oxytocin, the mothers suffered uncontrolled postpartum hemorrhage, leading to their demise.
Why Oxytocin Is Critical in C‑Section Deliveries
Oxytocin is a naturally occurring hormone that provokes uterine contractions during labor and facilitates milk ejection after birth. Synthetic analogues such as Syntocinon and Pitocin are routinely used by obstetricians to induce labor or to tighten the uterus after a C‑section, acting like a medical tourniquet that prevents excessive bleeding. In the Kota case, the counterfeit product failed to provide this essential uterine tone, allowing the placenta‑attachment vessels to remain open and bleed profusely.
Regulatory Response and Industry Fallout
The World Health Organization (WHO) formally requested a detailed report from the Indian government regarding the alleged supply of spurious oxytocin to Kota’s public hospitals. Concurrently, the Central Drugs Standard Control Organisation (CDSCO) and state drug regulators revoked the manufacturing licences of Jackson Laboratories’ units in Punjab and Himachal Pradesh after joint inspections uncovered serious compliance breaches.
India’s Broader Drug‑Safety Challenge
This episode adds to a growing list of drug‑quality scandals in India, ranging from sub‑standard antibiotics to toxic cough syrups contaminated with diethylene glycol that claimed the lives of children. Such incidents erode public confidence and jeopardize India’s ambition to become the world’s pharmacy. Repeated lapses point to systemic weaknesses in manufacturing oversight, quality assurance, and post‑market surveillance.
Path Forward: Mandatory Multi‑Layer Testing
In response, the Rajasthan state government ordered the immediate roll‑out of a three‑layer drug testing system. The framework mandates random batch sampling, rigorous laboratory validation, and continuous monitoring, with swift licence cancellation for any non‑compliant entity. Experts argue that a nationally harmonised version of this system could dramatically reduce the risk of counterfeit or sub‑standard medicines reaching patients.
